Roman Butler Fullerton & Co. purchased a new position in shares of Altria Group, Inc. (NYSE:MO – Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,112 shares of the company’s stock, valued at approximately $205,000.
Several other hedge funds have also modified their holdings of the stock. MFA Wealth Advisors LLC acquired a new position in Altria Group during the second quarter valued at approximately $27,000. Hobbs Group Advisors LLC bought a new stake in shares of Altria Group in the second quarter worth $30,000. Valley Wealth Managers Inc. increased its stake in shares of Altria Group by 63.9% in the second quarter. Valley Wealth Managers Inc. now owns 667 shares of the company’s stock worth $30,000 after buying an additional 260 shares during the last quarter. Fairman Group LLC increased its stake in Altria Group by 85.1% during the third quarter. Fairman Group LLC now owns 892 shares of the company’s stock valued at $46,000 after purchasing an additional 410 shares during the last quarter. Finally, Lynx Investment Advisory bought a new stake in Altria Group during the second quarter valued at $44,000. 57.41% of the stock is owned by institutional investors and hedge funds.
Altria Group Stock Performance
Shares of NYSE MO opened at $53.88 on Tuesday. The stock has a market cap of $91.93 billion, a price-to-earnings ratio of 9.10, a PEG ratio of 3.11 and a beta of 0.64. The business has a 50 day simple moving average of $51.44 and a 200 day simple moving average of $48.57. Altria Group, Inc. has a 52 week low of $39.25 and a 52 week high of $54.95.
Altria Group Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, October 10th. Stockholders of record on Monday, September 16th were given a $1.02 dividend. This represents a $4.08 annualized dividend and a dividend yield of 7.57%. This is a boost from Altria Group’s previous quarterly dividend of $0.98. The ex-dividend date was Monday, September 16th. Altria Group’s dividend payout ratio is currently 68.92%.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on MO. Citigroup boosted their price target on shares of Altria Group from $44.50 to $48.00 and gave the company a “neutral” rating in a report on Tuesday, October 8th. Bank of America dropped their price target on shares of Altria Group from $57.00 to $53.00 and set a “neutral” rating on the stock in a research report on Tuesday, October 15th. Barclays boosted their price target on shares of Altria Group from $43.00 to $45.00 and gave the stock an “underweight” rating in a research report on Monday, September 9th. UBS Group boosted their price objective on Altria Group from $39.00 to $41.00 and gave the stock a “sell” rating in a report on Monday, September 9th. Finally, Stifel Nicolaus boosted their price objective on Altria Group from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Altria Group has a consensus rating of “Hold” and a consensus price target of $51.17.
View Our Latest Analysis on MO
About Altria Group
Altria Group, Inc, through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and snus products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand.
Further Reading
- Five stocks we like better than Altria Group
- How to Find Undervalued Stocks
- Intel: Is Now the Time to Be Brave?Â
- 3 Warren Buffett Stocks to Buy Now
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- 5 discounted opportunities for dividend growth investors
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Altria Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altria Group and related companies with MarketBeat.com's FREE daily email newsletter.